Sex | | | 0.25 |
Male | Ref. | Ref. | |
Female | 1.71 | 0.68, 4.29 | |
Age | 0.97 | 0.93, 1.00 | 0.064 |
Age group | | | 0.45 |
30–39 years | Ref. | Ref. | |
40–49 years | 0.70 | 0.03, 6.36 | |
50–59 years | 0.57 | 0.03, 4.57 | |
60–69 years | 0.74 | 0.04, 5.70 | |
≥70 years | 0.25 | 0.01, 1.99 | |
Number of comorbidities | | | 0.73 |
0 | Ref. | Ref. | |
1 | 1.50 | 0.44, 5.09 | |
≥2 | 1.55 | 0.48, 4.79 | |
BMI | | | 0.17 |
<25 kg/m2 | Ref. | Ref. | |
≥25 kg/m2 | 0.37 | 0.11, 1.05 | |
Incubation period | 1.01 | 0.90, 1.13 | 0.91 |
Length of hospital stay | 1.01 | 0.97, 1.05 | 0.78 |
Vaccination | | | 0.10 |
1 dose, <2 weeks before infection | Ref. | Ref. | |
1 dose, >2 weeks before infection | 0.18 | 0.02, 1.41 | |
Not vaccinated | | | 0.10 |
Highest respiratory support technique during hospitalisation | | | 0.012 |
HFNC or NIV or IMV | Ref. | Ref. | |
Oxygen via nasal cannula or face mask | 0.13 | 0.01, 0.68 | |